Yesid Alvarado Valero

Associate Professor

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Yesid Alvarado Valero is an Associate Professor at The University of Texas MD Anderson Cancer Center in the United States. His research primarily focuses on acute myeloid leukemia, myelodysplastic syndromes, and the effects of various therapeutic interventions, including CDK9 inhibitors and venetoclax regimens. Recent articles authored by Professor Alvarado Valero delve into the efficacy of treatments for relapsed/refractory leukemia and explore new criteria for assessing patient outcomes.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2020

Year:

2020

Year:

2020

Collaborators (2)

Aaron Katz

Research Assistant Professor

University of Kansas Medical Center

UNITED STATES

View details

Musa Yilmaz

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Yesid Alvarado Valero

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia

A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies

A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms

Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMML

Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients

Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission

Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents

Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia.

Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Collaborators (2)

Aaron Katz

Musa Yilmaz

Make your next move.